Australian biotech company Vaxxas, in partnership with the Queensland Government, today announced the opening of its global headquarters and production facilities in Brisbane.
The custom-built 5500-square-meter (60,000-square-foot) Vaxxas biomedical facility is the first production facility of its kind designed to expand Vaxxas’ needle-free vaccine generation platform, the high-density microarray. (HD-MAP), for late-stage clinical trials and first-in-class products.
The Vaxxas biomedical facility is expected to generate up to two hundred local professional jobs and produce millions of vaccine patches in line with the previous year, fully in line with the national one, which will contribute to Queensland’s local economy.
The Queensland Government has provided investments and operations to Vaxxas for the progression of the site.
Additional investment was provided through the Australian Federal Government as a component of its Modern Manufacturing Initiative for the installation of specialist production infrastructure.
The opening was chaired by Deputy Prime Minister, Minister of State Development, Infrastructure, Local Government and Planning and Minister Assistant to the Prime Minister for Olympic and Paralympic Games Infrastructure, Dr. Steven Miles.
“Queensland is fast becoming a global hub of research and innovation thanks to the Palaszczuk government’s investment in services like this. Economic Development Queensland has worked hard with Vaxxas to advance the design and approval of this facility, so it’s fantastic to be here to open it,” said Miles.
“The Palaszczuk government is committed to supporting local biomedical startups to grow effectively and keep this innovation and our most productive and brilliant researchers on our soil.
“This world-class generation has the prospect of playing an important role in pandemic preparedness by allowing vaccines to be rolled out temporarily and smoothly in our communities.
“Queensland is becoming more and more powerful as a place to work and invest in science, and Vaxxas is an example of a local biotech tale of good fortune that we want to stay here in Queensland. The opening of the Vaxxas biomedical facility on Brisbane’s north shore brings us one step closer to achieving this goal,” concluded Miles.
Vaxxas’ proprietary HD-MAP generation platform has the prospect of vaccination by creating vaccines that are easy to use, possibly allow self-administration, and are robust at room temperature, reducing the complexities and costs related to refrigerated distribution required for many existing vaccines. Vaccines.
Vaxxas CEO David Hoey said the opening of the facility marked a milestone for the biotech company founded in 2011 on studies at the University of Queensland.
“The Vaxxas Biomedical Facility will firmly position Australia at the forefront of vaccine generation innovation, with the state of Queensland and Australian federal governments.
The facility will in particular increase our production capacity, creating new local and professional jobs, while allowing Vaxxas to advance the late-stage clinical trials that will bring our first advertising vaccines to market,” said Hoey.
“With several completed and successful human clinical trials involving over 500 participants; ongoing Australian phase I clinical studies for COVID-19 and seasonal influenza; and other U. S. government-funded pandemic influenza vaccine studies.
The Vaxxas biomedical facility offers a scalable product production procedure that can potentially be replicated through Vaxxas nationally and globally as demand for its generation of proprietary vaccine patches increases.
The facility features two separate Good Manufacturing Practices (GMPs), qualified aseptic cleanrooms, medical device production space, device meeting clean room, and supporting infrastructure that adds labs and offices.
The vaccines will be manufactured according to criteria from the Australian Therapeutic Goods Administration, the U. S. Food and Drug Administration, and the U. S. Food and Drug Administration. The U. S. Food and Drug Administration and other global fitness regulators are based on the U. S. Food and Drug Administration, the European Medicines Agency and other global fitness regulators.
Manufacturers’ Monthly is a business-to-business magazine and a valuable reference tool for all members of the manufacturing industry. The magazine is highly targeted and reads through the main resolution makers who acquire and specify production apparatus and services. It is also widely read through suppliers in the productive industry.